The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) is considering certain changes to the current meningococcal vaccination schedule. Here's why the ACIP should scrap that proposal.
The FDA approved Pfizer’s Penbraya for vaccinating against five bacterial groups that can cause meningococcal disease. Pfizer already has vaccines covering those groups, but Penbraya addresses all of them in a single vaccine, making dosing easier for patients.
We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.